All for Joomla All for Webmasters

D3 - Session 4 - D-Dimer in Cancer and VTE

Rate this item
(1 Vote)

Did you attend this webinar? Get your certificate

 

Questions/answers on the Session 4 - D-Dimer in Cancer and VTE

A1. Thromboprophylaxis is not routinely recommended for all cancer patients. Though cancer patients are more likely than people without cancer to develop VTE, a number of cancer specific factors, such as the bleeding tendency at the site of the cancer, or a thrombocytopenia caused by chemotherapy can increase the bleeding risk in particular during anticoagulant treatment. Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic primary prophylaxis as well as the effective treatment to reduce the risk of VTE recurrence and mortality, as suggest by most international guidelines.

In hospitalized medical cancer patients, primary pharmacologic thromboprophylaxis should be offered, to all patients who have active malignancy, particularly in association with acute medical illness or reduced mobility, in the absence of bleeding or other contraindications.

To the same guise, in the setting of patients with cancer undergoing surgery, in particular those undergoing major surgical intervention, primary pharmacologic thromboprophylaxis is recommended with either unfractionated heparin (UFH) or LMWH unless contraindicated because of active bleeding, or high bleeding risk, or other contraindications. A combined regimen of pharmacologic and mechanical thromboprophylaxis may improve efficacy, especially in the highest-risk patients.
Concerning primary prophylaxis in ambulatory cancer patients undergoing anti-cancer drug treatments, who are the great majority of the cancer population, the decision is much more complex. Routine pharmacologic thromboprophylaxis is not indicated for all of them because the thrombotic risk is very variable among these individuals, depending on the type of cancer, the type of anti-cancer therapy, the stage of the disease, etc. It is therefore very important, in this setting, to identify outpatients who are at ‘high-risk’ and can most benefit from antithrombotic prophylaxis, in whom the thrombotic risk outweighs the bleeding risk of anticoagulant drugs. High-risk outpatients with cancer (Khorana score of 2 or more prior to starting a new systemic chemotherapy regimen) may be offered thromboprophylaxis with apixaban, rivaroxaban, or low-molecular-weight heparins (LMWH) provided there are no significant risk factors for bleeding and no drug-drug interactions. Consideration of such therapy should be accompanied by a discussion with the patient about the relative benefits and harms, drug cost, and duration of prophylaxis in this setting.

A2. A single test is usually not sufficient to identify the level of VTE risk. Current guidelines suggest to classify patients as being at low, intermediate, or high risk for VTE based on validated risk assessment models (RAM) which include clinical risk factors and biological risk factors (i.e., Khorana score), and do not suggest to rely on only a single laboratory test. However, recent studies on patients with cancer-associated thrombosis (CAT), have identified D-dimer as one of the laboratory biomarkers useful for the identification of patients at high thrombotic risk, in combination with clinical and biological variables of the Khorana score (Vienna-CAT, Pabinger 2009), or in combination with only one clinical variable, i.e. the tumor site (Pabinger 2018).

A3. Several proteins could be measured for evaluating endothelial damage because they are released by perturbed and/or activated endothelial cells, i.e.: soluble thrombomodulin, von Willebrand factor, E-selectin, t-PA, PAI, TFPI. Also the presence of circulating endothelial cells is a direct evidence of endothelial injury. Of interest, endothelial cells express different markers in different disease states reflecting the different mechanisms of endothelial injury.

However, most of these biomarkers are not routinely assessed by all laboratories, unless for research purposes. In this scenario the measurement of the vWF for assessment of endothelial damage is the most practical, as it is a diagnostic tool for specialized second level laboratories and therefore is more widely accessible.

A4. Risk assessment models can certainly help clinicians to select high-risk patients candidates to thromboprophylaxis, avoiding the use of anticoagulants in patients at low VTE risk. However, at present the available RAMs still have some limitations. Improvements in risk model rules have been made by modifications of the Khorana score, i.e. the PROTECHT, the CONKO and the Vienna-CATS scores, or by creation of a new score, i.e. the COMPASS-CAT.

At this time, the best externally validated RAM remains the Khorana score, which also has the advantage of being composed by easily available variables.

A5. LMWH are the reference molecule for the long-term treatment of venous thromboembolism (VTE) in cancer patients. The anti-factor Xa activity test is not routinely required in cancer patients treated with LMWH, but it may be suggested in particular cases i.e. renal insufficiency, obesity, weight <40 kg, thrombotic recurrence or active bleeding. In the case of UFH treatment, anticoagulant treatment monitoring is required, usually by APPT measurement, but also anti-Xa activity assay can be used.

A6. The influence of thrombophilia, such as Factor V Leiden, on the thrombotic risk of cancer patients has been shown. However, on a routine basis, it is not recommended to performed thrombophilic screening in these patients because of in patients with cancer the risk of thrombosis due to cancer per se possibly outweighing the contribution of thrombophilic factors.

Additional Info

  • Business Line: Hemostasis
  • Language: English
  • Speaker(s): Anna Falanga
  • Recorded Date: Wednesday, 31 March 2021
  • Duration: 25:30
Read 2907 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection